Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results

Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. Oncology-focused...
Streetwise Reports | March 3, 2020 |

Coronavirus Propels Telemedicine into the Spotlight

Summary: Coronavirus could be the game changer that propels telemedicine into the mainstream. Virtual clinical services have been around since the '90s but had failed to catch on. Now, a concerted effort by healthcare providers, insurance companies, the federal government...
Streetwise Reports | March 27, 2020 |

Aleafia Health CEO Talks Expansion Plans and Progress

(Image via Aleafia Health. Click image to enlarge) When a business strategy works and can be expanded, the smart bet is to double down. That’s the logic in any industry, and the still-growing cannabis market is no different. That&CloseCurlyQuote...
Omri Wallach | September 27, 2019 |

Immunomedics Shares Double as Phase 3 Breast Cancer Trial Achieves 'Compelling' Efficacy Data

Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer. ...
Streetwise Reports | April 7, 2020 |

Buzz on the Bullboards: Who benefits from the latest stock market rally?

It was a more nuanced performance for stock markets in Toronto and New York this week with notable gains and splits between indices capturing investor attention. The TSX surged to highs not seen in a month, buoyed by optimism, while in the United States, some stocks ...
Jonathon Brown | May 9, 2024 |

Why This Psychedelics Company is Focused on Weight Management

Psychedelics are transforming so many aspects of our everyday lives — from treating mental health conditions to weight management and obesity. Companies like NeonMind Biosciences ( CSE:NEON , OTCQB:NMDBD , Forum ) are at the forefront of this innovation ...
Jocelyn Aspa | May 4, 2022 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study

Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19. Clinical-stage biopharmaceutical company Edesa B...
Streetwise Reports | June 16, 2020 |

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
Streetwise Reports | November 27, 2019 |

Buzz on the Bullboards: Do the Dead Cats Bounce?

(Image via CGX Energy Inc.) You’ve heard that what goes up must come down, but in the stock trading world, what goes down should come up. Even a dead cat can bounce if it falls from high enough up, right? The markets coined this term believing th...
Stockhouse Editorial | May 11, 2022 |
1 2 3 4 5 6 7 8 9 10 ...